- $34.93m
- $9.99m
- $4.01m
CervoMed jumps on dementia drug trial data
U.S. STOCKS ON THE MOVE-PagerDuty, CervoMed, Talen Energy
CervoMed jumps on dementia drug trial data
CervoMed Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Cervomed Co Enters Sales Agreement With Leerink Partners LLC
CervoMed Inc expected to post a loss of 66 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-American Electric Power, Block and Lenz Therapeutics
U.S. STOCKS ON THE MOVE-MeiraGTx, CervoMed, Natgas companies
CervoMed up after Jones Research upgrades rating
U.S. STOCKS ON THE MOVE-HubSpot, Casey's General Stores, ANI Pharma
U.S. STOCKS ON THE MOVE-CoreCivic, Alphabet, Vail Resorts
U.S. STOCKS ON THE MOVE-CleanSpark, MoneyLion, CoreCivic
U.S. STOCKS ON THE MOVE-Boeing, Alaska Air, Centene
CervoMed tumbles after dementia drug fails to meet mid-stage trial goals
CervoMed's dementia drug fails to meet mid-stage trial goals (updated)
CervoMed's dementia drug fails to meet mid-stage trial goals
Brief: CervoMed's Neflamapimod gets U.S. FDA Orphan Drug Designation for treating Frontotemporal Dementia
Brief: CervoMed Announces Key Senior Leadership Appointments
CervoMed Inc reports results for the quarter ended September 30 - Earnings Summary